By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The pharmaceutical sector originated in Europe. The biggest and most significant pharmaceutical markets are still in Europe and the United States. The majority of R&D investments are made by their enterprises, which remain major players on the international stage.
An organisation of the European Union (EU), the European Medicines Agency (EMA), is in charge of monitoring and evaluating pharmaceuticals.With funding from the European Union, the pharmaceutical industry, and indirect support from member states, the EMA was established with the declared goal of harmonising the activities of existing national medicine regulatory agencies.
It was hoped that this plan would eliminate the protectionist tendencies of sovereign states unwilling to approve new drugs that might compete with those already produced by domestic drug companies in addition to reducing the annual costs that drug companies incurred by having to obtain separate approvals from each member state.
The Europe pharmaceuticals market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Building on the work of the Innovative Medicines Initiative, the Innovative Health Initiative is a public-private joint venture that seeks to strengthen cooperation between the European Pharmaceutical and Related Industries and the European Commission.
The Innovative Medicines Initiative (IMI), which showed the value of a cooperative PPP model between the European Pharmaceutical Industry and the EC, is directly related to the Innovative Health Initiative (IHI).
Other industries have joined the PPP in addition to the European Pharmaceutical Industry’s ongoing participation (through EFPIA), with the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR), Medtech Europe, EuropaBio, and Vaccines Europe being the most notable.
As a result, the programme will be able to benefit from the ongoing technological convergence that integrates the digital, diagnostics, imaging, pharmaceutical, and biotech industries. More importantly, this would hasten innovation throughout the entire gamut of healthcare activities, from illness prevention and early diagnosis to treatment and care.
